Chapter 3: Pharmacodynamics — Module 5: Drug Targets — Enzymes, Transporters, Ion Channels and Nuclear Receptors
1. Imatinib revolutionized CML (chronic myeloid leukemia) treatment by achieving near-normal life expectancy in most patients. Its mechanism involves selective BCR-ABL (breakpoint cluster region-Abelson) kinase inhibition. Which of the following best explains why selective inhibition of a single kinase can produce such dramatic clinical outcomes in CML?
A) CML cells express uniquely high concentrations of BCR-ABL protein compared to all other oncogenic kinases, making BCR-ABL more susceptible to inhibition at standard drug concentrations than any other kinase target
B) Imatinib is not selective for BCR-ABL -- it broadly inhibits all tyrosine kinases in CML cells simultaneously, and the combined inhibition of multiple proliferative pathways produces the clinical response
C) CML cells have lost all DNA repair mechanisms due to BCR-ABL-driven genomic instability, making them unable to develop resistance to imatinib even if BCR-ABL inhibition is overcome
D) BCR-ABL is the single constitutively active driver of CML cell proliferation and survival -- CML cells depend entirely on continuous BCR-ABL signaling (oncogene addiction); inhibiting BCR-ABL simultaneously removes the proliferative drive and the survival signal that prevents apoptosis, producing selective cytotoxicity in CML cells while sparing normal cells whose growth does not depend on BCR-ABL; this concept of oncogene addiction is the pharmacodynamic foundation for all targeted cancer therapies
E) Imatinib works by activating the immune system rather than by direct kinase inhibition -- it modifies BCR-ABL protein to create a neoantigen that stimulates T-cell-mediated tumor immunity
ANSWER: D
Rationale:
The dramatic efficacy of imatinib in CML illustrates the concept of oncogene addiction -- the dependence of cancer cells on a single dominant oncogenic signal for their proliferation and survival. CML cells are driven entirely by the constitutively active BCR-ABL tyrosine kinase created by the Philadelphia chromosome translocation. BCR-ABL activates multiple downstream pathways (RAS/MAPK (mitogen-activated protein kinase), PI3K (phosphoinositide 3-kinase)/AKT, STAT5 (signal transducer and activator of transcription 5)) that together suppress apoptosis, promote cell cycle entry, and drive unchecked proliferation. CML cells become so dependent on this single constitutive signal that they cannot maintain viability without it -- this is oncogene addiction. When imatinib blocks BCR-ABL kinase activity, it simultaneously removes the proliferative drive and the anti-apoptotic signal that CML cells require. Normal hematopoietic cells do not depend on BCR-ABL (they do not carry the Philadelphia chromosome) and are therefore spared. This selectivity -- for the oncogene-addicted tumor cells over normal cells -- is the pharmacodynamic basis for the extraordinary efficacy-to-toxicity ratio of targeted therapy in oncogene-driven cancers. The oncogene addiction concept has been validated across multiple targeted therapies: BRAF (B-Raf proto-oncogene) V600E inhibitors in melanoma, EGFR (epidermal growth factor receptor) inhibitors in EGFR-mutant NSCLC (non-small cell lung cancer), and ALK (anaplastic lymphoma kinase) inhibitors in ALK-rearranged lung cancer.
Option A: Option A is incorrect -- BCR-ABL protein overexpression relative to other kinases is not the explanation; the selectivity arises from the cancer cells' exclusive dependence on BCR-ABL signaling, not from differential protein concentrations.
Option B: Option B is incorrect -- imatinib is selective for BCR-ABL (and KIT (stem cell factor receptor) and PDGFR (platelet-derived growth factor receptor)) and does not broadly inhibit all tyrosine kinases.
Option C: Option C is incorrect -- CML cells do develop resistance to imatinib, most commonly through BCR-ABL kinase domain mutations (particularly T315I); DNA repair is not uniformly lost.
Option E: Option E is incorrect -- imatinib is a direct kinase inhibitor, not an immunomodulator; its primary mechanism is competitive inhibition of the BCR-ABL ATP-binding site.
2. The glucocorticoid receptor (GR) produces both the desired anti-inflammatory effects and the unwanted metabolic side effects of glucocorticoid therapy. Which of the following correctly explains the pharmacodynamic mechanism underlying this distinction?
A) Anti-inflammatory effects arise primarily from transrepression -- GR physically interacting with and tethering transcription factors NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) and AP-1 (activator protein 1) at inflammatory gene promoters, blocking their transcriptional activity without directly binding DNA; metabolic side effects (hyperglycemia, osteoporosis, adrenal suppression) arise primarily from transactivation -- GR homodimers binding palindromic GREs (glucocorticoid response elements) in DNA and directly activating transcription of gluconeogenic enzymes, RANKL (receptor activator of nuclear factor kappa-B ligand), and CRH (corticotropin-releasing hormone)/ACTH-suppressing genes; the separation of these two mechanisms has driven research into dissociated glucocorticoids that retain transrepression while minimizing transactivation
B) Anti-inflammatory effects arise from GR activation in lymphocytes only, while metabolic effects arise from GR activation in hepatocytes and adipocytes -- organ-selective GR agonists could theoretically produce anti-inflammatory effects without metabolic toxicity
C) Anti-inflammatory effects require only partial GR occupancy (below 30%), while metabolic effects require full GR occupancy (above 80%) -- lower glucocorticoid doses should produce anti-inflammatory effects without metabolic toxicity, but clinical practice has not confirmed this dose-response separation
D) Anti-inflammatory effects arise from membrane-bound GR signaling through rapid non-genomic mechanisms (within minutes), while metabolic effects arise from nuclear GR-mediated gene transcription (over hours to days) -- the non-genomic anti-inflammatory pathway is pharmacologically separable from the genomic metabolic pathway
E) Anti-inflammatory effects are mediated by GR-alpha while metabolic effects are mediated by GR-beta -- the two splice variants have distinct tissue distribution and can be targeted selectively by different glucocorticoid agonists
ANSWER: A
Rationale:
The distinction between transrepression and transactivation by the glucocorticoid receptor is one of the most pharmacologically important concepts in nuclear receptor pharmacology and has driven decades of drug discovery aimed at "dissociated" glucocorticoids. Both mechanisms involve the same GR protein after ligand binding -- the difference is in how the activated GR interacts with DNA and transcription factors. Transrepression: activated GR can interact directly with the p65 subunit of NF-kappaB and the Jun component of AP-1 through protein-protein tethering interactions, preventing these transcription factors from activating inflammatory gene promoters (IL-1, IL-6, TNF-alpha, COX-2 (cyclooxygenase-2), iNOS (inducible nitric oxide synthase)). Crucially, this does not require GR to bind DNA directly. This mechanism is responsible for most of the anti-inflammatory and immunosuppressive effects of glucocorticoids. Transactivation: GR homodimers bind palindromic GRE (glucocorticoid response element) sequences in the promoters of metabolic target genes, directly activating their transcription. Genes activated by this mechanism include PEPCK (phosphoenolpyruvate carboxykinase, driving gluconeogenesis), tyrosine aminotransferase (hepatic gluconeogenesis), genes regulating adipocyte differentiation and fat redistribution, RANKL (promoting osteoclast activity and osteoporosis), and the genes encoding key HPA axis feedback proteins. The metabolic side effects of glucocorticoids -- hyperglycemia, cushingoid fat redistribution, osteoporosis, and HPA axis suppression -- arise primarily from GRE-mediated transactivation.
Option B: Option B is incorrect -- GR is expressed in essentially all nucleated cells; tissue-selective GR signaling does occur but is not explained by lymphocyte-only anti-inflammatory activity.
Option C: Option C is incorrect -- the dose-response curves for anti-inflammatory and metabolic effects overlap substantially; dose reduction alone does not reliably separate the effects.
Option D: Option D is incorrect -- while rapid non-genomic GR effects do occur, the primary anti-inflammatory mechanisms of glucocorticoids are genomic (transrepression), requiring hours for full effect.
Option E: Option E is incorrect -- GR-beta is a splice variant that acts as a dominant negative inhibitor of GR-alpha but is not specifically responsible for metabolic effects; this is not the established clinical pharmacodynamic distinction.
3. A patient is started on prednisolone 40 mg daily for autoimmune hepatitis. Six weeks later her disease is well-controlled and the rheumatologist begins tapering. Despite prednisolone's plasma half-life of only 2-3 hours, the HPA (hypothalamic-pituitary-adrenal) axis remains suppressed and the patient requires a slow taper over months rather than days. Which pharmacodynamic principle best explains this prolonged biological duration of action far exceeding the plasma half-life?
A) Prednisolone is converted to an active metabolite (prednisone) that has a plasma half-life of 60 hours and maintains GR occupancy long after prednisolone itself is cleared from plasma
B) The glucocorticoid receptor undergoes irreversible covalent modification by prednisolone, producing persistent GR activation that cannot be reversed until new receptor protein is synthesized over weeks
C) Prednisolone has an extremely large volume of distribution and accumulates in adipose tissue, slowly releasing into plasma over months and maintaining biological effects long after the last dose through a pharmacokinetic depot mechanism
D) Prednisolone has a plasma half-life of 3 hours but an effect-site half-life in the pituitary corticotroph cells of 60 hours due to slow receptor dissociation -- HPA suppression persists until prednisolone completely dissociates from pituitary GRs
E) Glucocorticoids act through nuclear receptor-mediated gene transcription -- the newly synthesized proteins responsible for HPA suppression (including feedback inhibition of CRH and ACTH release) have their own biological half-lives that determine how long the pharmacodynamic effect persists; even after the drug is cleared from plasma, the gene products already synthesized (mRNAs, proteins) continue to exert their effects until they are themselves degraded; additionally, chronic exposure produces structural adrenocortical atrophy requiring weeks to months of recovery regardless of drug plasma levels
ANSWER: E
Rationale:
This question illustrates the fundamental pharmacodynamic concept that drug effect duration is not determined by plasma half-life alone -- it is determined by the duration of the downstream biological consequences of receptor activation. Prednisolone binds the GR (plasma half-life ~2-3 hours, biological half-life ~12-36 hours for the pharmacodynamic effects), which translocates to the nucleus and activates transcription of multiple genes. The mRNAs produced have their own half-lives (hours to days), and the proteins translated from those mRNAs have their own half-lives (days to weeks for structural proteins). The anti-inflammatory proteins induced and the pro-inflammatory proteins suppressed by glucocorticoids persist for variable periods after the drug is cleared from plasma. For HPA axis suppression specifically: the gene products responsible for feedback inhibition of CRH and ACTH persist. More importantly, with prolonged daily glucocorticoid exposure, structural atrophy of the adrenal cortex develops -- the zona fasciculata loses its capacity for cortisol synthesis due to sustained absence of ACTH stimulation. This adrenocortical atrophy is a structural pharmacodynamic consequence that outlasts plasma drug levels by weeks to months; recovery requires regeneration of adrenocortical cells and restoration of steroidogenic enzyme expression. This explains why patients on chronic glucocorticoids must be tapered gradually over months.
Option A: Option A is incorrect -- prednisone is the prodrug that is converted to prednisolone (not the reverse); prednisolone is the active form, and its metabolite has no 60-hour half-life.
Option B: Option B is incorrect -- GR binding by glucocorticoids is reversible; glucocorticoids are not covalent receptor modifiers.
Option C: Option C is incorrect -- while prednisolone has some adipose tissue distribution, the depot mechanism is not the primary explanation for months-long HPA suppression.
Option D: Option D is incorrect -- prednisolone's dissociation from pituitary GRs follows normal non-covalent kinetics; the prolonged effect is pharmacodynamic (gene expression consequences and adrenal atrophy), not due to slow receptor dissociation.
4. The RAS (rat sarcoma viral proto-oncogene)-MAPK cascade is activated downstream of multiple receptor tyrosine kinases and is mutated in approximately 30% of all human cancers. Why has RAS itself been historically difficult to target pharmacologically, and what made sotorasib's approach to KRAS G12C successful?
A) RAS is located on the inner leaflet of the plasma membrane rather than in the cytoplasm, making it physically inaccessible to small molecules that cannot cross biological membranes -- sotorasib was designed with a specific membrane-targeting domain that delivers it to the inner leaflet where KRAS G12C is located
B) All four RAS isoforms (HRAS (Harvey RAS), KRAS (Kirsten RAS), NRAS (neuroblastoma RAS), MRAS (muscle RAS)) are encoded by the same gene and are pharmacodynamically interchangeable -- targeting any single isoform leaves the others to maintain signaling, making pan-RAS inhibition necessary; sotorasib selectively targets all four isoforms simultaneously
C) RAS has picomolar affinity for GTP (guanosine triphosphate) -- making competitive inhibition at the guanine nucleotide binding site impossible under physiological GTP concentrations; additionally, RAS has a smooth surface with no obvious drug-binding pockets; the G12C mutation uniquely introduces a reactive cysteine adjacent to the GDP (guanosine diphosphate)-bound inactive pocket, allowing sotorasib to form an irreversible covalent bond with this cysteine and lock KRAS G12C in the inactive GDP-bound state without needing to compete with GTP
D) RAS has no enzymatic activity of its own -- it acts purely as a scaffold protein bringing kinases into proximity; because scaffold proteins have no enzymatic active site, they cannot be inhibited by conventional enzyme inhibitor approaches; sotorasib targets the downstream kinase RAF (rapidly accelerated fibrosarcoma kinase) rather than RAS itself
E) RAS mutations in cancer prevent GTP hydrolysis but simultaneously reduce GTP binding affinity -- creating a window where sotorasib can competitively displace GTP by binding with higher affinity than the mutant RAS, restoring the GDP-bound inactive state
ANSWER: C
Rationale:
RAS was recognized as an oncogene in the 1980s but was considered undruggable for approximately 40 years for two fundamental reasons. First, RAS has picomolar affinity for GTP -- under physiological GTP concentrations of approximately 0.5 mM, a competitive inhibitor would need extraordinary affinity to displace GTP, far exceeding what medicinal chemistry could practically achieve. Second, unlike kinase active sites (which have well-defined ATP-binding pockets with excellent druggable geometry), the surface of RAS protein is relatively smooth without the deep hydrophobic pockets that allow selective small-molecule binding. KRAS G12C mutations change glycine-12 to cysteine, introducing a unique reactive sulfhydryl group adjacent to the switch II pocket of KRAS in its GDP-bound (inactive) state. Sotorasib exploits this in two ways: it forms an irreversible covalent bond with the mutant cysteine (irreversible covalent targeting), and it targets the GDP-bound inactive form rather than the active GTP-bound form. By locking KRAS G12C permanently in the GDP-bound state, sotorasib prevents the GTP loading that activates KRAS and downstream MAPK signaling. Because wild-type KRAS (glycine-12, no cysteine) cannot be covalently modified, sotorasib is exquisitely selective for the mutant protein.
Option A: Option A is incorrect -- small molecules routinely access membrane-associated proteins through diffusion; KRAS membrane anchoring is not the barrier to drug development; the nucleotide binding characteristics are.
Option B: Option B is incorrect -- the four RAS isoforms (HRAS, KRAS, NRAS, and the less common RRAS (related RAS viral oncogene homolog), MRAS etc.) are encoded by different genes and have different expression patterns and transformation potencies; sotorasib specifically targets KRAS G12C, not all isoforms.
Option D: Option D is incorrect -- RAS is a GTPase with enzymatic activity (it hydrolyzes GTP to GDP); oncogenic mutations impair this GTPase activity; sotorasib does not target RAF.
Option E: Option E is incorrect -- oncogenic RAS mutations do not reduce GTP binding affinity; they reduce GTPase activity, trapping RAS in the GTP-bound active state; sotorasib uses covalent binding to the GDP-bound form, not competitive GTP displacement.
5. A patient with rheumatoid arthritis on long-term prednisolone 10 mg daily is scheduled for a total hip replacement. The anesthesiologist orders stress-dose steroids perioperatively. Which pharmacodynamic principle underlies this clinical decision?
A) Surgery increases hepatic CYP3A4 activity through inflammatory cytokine induction, accelerating prednisolone metabolism and reducing its plasma half-life below the level needed to maintain anti-inflammatory effects -- stress-dose coverage compensates for accelerated drug clearance
B) Chronic prednisolone therapy suppresses the HPA axis and causes adrenal cortex atrophy -- the atrophied adrenal glands cannot generate the physiological cortisol surge (normally 75-150 mg cortisol equivalent/day under surgical stress, compared to baseline 15-25 mg/day) required to maintain hemodynamic stability and metabolic homeostasis during surgery; stress-dose glucocorticoid replacement prevents adrenal crisis in a patient whose own adrenal reserve is insufficient to meet stress demands
C) General anesthesia blocks glucocorticoid receptor translocation to the nucleus through inhibition of nuclear transport proteins -- stress-dose steroids are required to overcome the anesthetic-mediated block in GR signaling and maintain anti-inflammatory coverage during the procedure
D) Surgery-induced cytokine release (IL-1, IL-6, TNF-alpha) competitively occupies GR ligand-binding sites, preventing prednisolone from binding its receptor -- higher-dose glucocorticoid administration is required to overcome this competitive cytokine-mediated receptor blockade
E) The usual prednisolone dose is calculated for oral bioavailability of approximately 80% -- perioperative fasting prevents oral administration, and IV stress-dose coverage at the same dose corrects the bioavailability difference between oral and IV routes
ANSWER: B
Rationale:
Perioperative stress-dose glucocorticoid coverage is a well-established clinical protocol for patients on chronic glucocorticoid therapy. The pharmacodynamic basis is HPA axis suppression and adrenal cortical atrophy from chronic exogenous glucocorticoid administration. Under normal physiological conditions, the adrenal glands respond to surgical stress (pain, anesthesia, blood loss, tissue trauma) by increasing cortisol secretion substantially -- from a basal output of approximately 15-25 mg cortisol equivalent per day to 75-150 mg per day during major surgery. This cortisol surge is essential for maintaining vascular tone (catecholamine sensitivity), hepatic gluconeogenesis, and immune regulation during the metabolic stress of surgery. In patients on chronic glucocorticoids, the HPA axis is suppressed -- ACTH secretion is blunted and the adrenal cortex is atrophied. When these patients undergo surgery, their own adrenals cannot mount the required cortisol response even if exogenous glucocorticoid is withheld. Without supplemental glucocorticoid coverage, they risk adrenal crisis: refractory hypotension, hypoglycemia, hyponatremia, and cardiovascular collapse. Current guidelines recommend hydrocortisone 50-100 mg IV at induction and every 8 hours for 24-48 hours after major surgery, then tapering back to the baseline dose.
Option A: Option A is incorrect -- CYP3A4 induction by surgical cytokines is not the established mechanism; the primary concern is adrenal insufficiency, not accelerated drug clearance.
Option C: Option C is incorrect -- general anesthetics do not block GR nuclear translocation; this mechanism has no clinical pharmacological basis.
Option D: Option D is incorrect -- cytokines do not competitively occupy GR ligand-binding sites; they signal through their own receptors (JAK (Janus kinase)-STAT, MAPK) and are actually the targets of GR-mediated suppression.
Option E: Option E is incorrect -- while IV administration is used perioperatively, the rationale is adrenal stress coverage, not correcting oral bioavailability differences; stress-dose glucocorticoid doses substantially exceed the patient's usual maintenance dose.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.